Skip to main content

Table 1 Cohort characteristics, n = 631

From: Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis

Characteristics
Age (years) at diagnosis (median, IQR) Median IQR
5.6 3.6–9.3
N %
Gender
 Male 177 28.1
 Female 454 71.9
Ethnicity
 Hispanic 95 15.1
Race
 Caucasian 519 82.3
 African-American 82 13
JDM Category
 Amyopathic 9 1.4
 Probable 490 77.7
 Definite 48 7.6
 Missing 84 13.3
History of Calcinosis 84 13.3
History of biologic use 242 38.4
 IVIG 225 35.7
 Rituximab 26 4.1
 Anti-TNFa 35 5.6
  Certolizumab 0 0
  Etanercept 22 3.5
  Golimumab 1 0.2
  Adalimumab 7 1.1
  Infliximab 13 2
 Abatacept 3 0.48
 Anti-IL1b 2 0.32
High glucocorticoid exposurec (n = 572) 316 50
  1. aComposite which includes etanercept, infliximab, adalimumab, certolizumab, golimumab
  2. bComposite which includes anakinra, canakinumab, rilonacept
  3. cComposite defined as history of IV pulse steroids and daily corticosteroids for ≥ 1 month